Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

China’s National Medical Products Administration has given the thumbs up to Akeso Pharmaceuticals Inc.’s ebdarokimab for treating moderate to severe plaque psoriasis in adults. An interleukin ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...

Compared with patients without psoriasis, pregnant patients with psoriasis are at higher risk for cardiovascular complications during delivery. Pregnant patients with psoriasis are at higher risk for ...

On lighter skin, plaque psoriasis can appear red ... but there aren’t nearly as many pictures of psoriasis on Black skin. This often leads people to the conclusion that psoriasis only develops ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. The singer, one half of the folk-rock duo Simon & Garfunkel, has teamed with Sun Pharma to discuss how ...

Obesity was linked to reduced long-term effectiveness of biologic therapy in patients with severe plaque psoriasis in a study, with dysregulated innate immune responses contributing to treatment ...